Britain is conducting a full review of its National Health Service contract with Palantir (PLTR), the US data analytics company, as political pressure mounts on the government to invoke a break clause when the deal's initial term expires in early 2027.

Eli Lilly (LLY) shares rose 4% after the drugmaker presented compelling data for retatrutide, its next-generation obesity treatment, fueling expectations among analysts and investors that the company will extend its dominance of the booming weight-loss market.

A cholera outbreak in Nigeria's northeastern Borno state has killed at least 74 people and infected more than 7,800 since early May, overwhelming health facilities in a region already weakened by years of conflict and displacement, according to Médecins Sans Frontières.

List prices for top brand-name drugs in the US have risen an average of 81% since launch, while prices for the same medicines fell an average of 13% across 19 other high-income countries, according to a report released by the AARP Public Policy Institute.

Massachusetts has sued a UnitedHealth Group (UNH) insurance unit, accusing it of defrauding the state's Medicaid program of more than $100mn by making elderly patients appear sicker than they were in order to inflate payments.

Eli Lilly (LLY) has agreed to acquire three vaccine developers in transactions valued at up to nearly $4 billion combined, marking a significant push by the weight-loss drug market leader into infectious-disease prevention.

Global health authorities and a clutch of drugmakers are racing to assemble medical defences against an Ebola outbreak in eastern Democratic Republic of Congo, where a rarer strain of the virus has left the world without a single approved vaccine or therapy to deploy.

UCB has reported data it says marks a milestone in the crowded market for psoriatic arthritis treatments, with its drug bimekizumab beating AbbVie's risankizumab in a direct comparison of joint outcomes.

South Korean biotechnology company AriBio said it has received an initial $10mn payment from China's Fosun Pharma (02196.HK) under a global exclusive licensing agreement for its Alzheimer's drug candidate AR1001, with the funds transferred just ten days after the deal was announced.

Drugmakers have wagered billions of dollars on a new class of cancer drugs targeting two well-known biological pathways — PD-1 and VEGF — but analysts say the industry's fixation on lung cancer may be obscuring a more compelling opportunity elsewhere.